LU91681I2 - "Eltrombopag,éventuellement sous forme d'un sel oud'un solvate (y compris sous forme d'un hydrate) pharmaceutiquement acceptable (REVOLADE)" - Google Patents

"Eltrombopag,éventuellement sous forme d'un sel oud'un solvate (y compris sous forme d'un hydrate) pharmaceutiquement acceptable (REVOLADE)"

Info

Publication number: LU91681I2
Authority: LU; Luxembourg
Prior art keywords: revolade; eltrombopag; solvate; hydrate; optionally
Prior art date: 2000-05-25

Application number

LU91681C

Other languages

English (en)

Other versions

LU91681I9 (fr

Original Assignee

Glaxosmithkline Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-25

Filing date

2010-04-21

Publication date

2010-06-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26901947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91681(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-04-21 Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc

2010-06-21 Publication of LU91681I2 publication Critical patent/LU91681I2/fr

2019-01-03 Publication of LU91681I9 publication Critical patent/LU91681I9/fr

Links

XDXWLKQMMKQXPV-QYQHSDTDSA-N eltrombopag Chemical compound CC1=NN(C=2C=C(C)C(C)=CC=2)C(=O)\C1=N/NC(C=1O)=CC=CC=1C1=CC=CC(C(O)=O)=C1 XDXWLKQMMKQXPV-QYQHSDTDSA-N 0.000 title 2
229960001069 eltrombopag Drugs 0.000 title 2
150000003839 salts Chemical class 0.000 title 1
239000012453 solvate Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
- C07D231/48—Oxygen atom in position 3 or 5 and nitrogen atom in position 4 with hydrocarbon radicals attached to said nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Diabetes (AREA)
Immunology (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Vehicle Body Suspensions (AREA)
Information Transfer Systems (AREA)
Hard Magnetic Materials (AREA)

LU91681C 2000-05-25 2010-04-21 "Eltrombopag,éventuellement sous forme d'un sel oud'un solvate (y compris sous forme d'un hydrate) pharmaceutiquement acceptable (REVOLADE)" LU91681I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US20708400P	2000-05-25	2000-05-25
US22892900P	2000-08-30	2000-08-30
PCT/US2001/016863 WO2001089457A2 (fr)	2000-05-25	2001-05-24	Mimiques de thrombopoietine

Publications (2)

Publication Number	Publication Date
LU91681I2 true LU91681I2 (fr)	2010-06-21
LU91681I9 LU91681I9 (fr)	2019-01-03

Family

ID=26901947

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU91681C LU91681I2 (fr)	2000-05-25	2010-04-21	"Eltrombopag,éventuellement sous forme d'un sel oud'un solvate (y compris sous forme d'un hydrate) pharmaceutiquement acceptable (REVOLADE)"

Country Status (30)

Country	Link
US (9)	US7160870B2 (fr)
EP (3)	EP1294378B1 (fr)
JP (2)	JP3813875B2 (fr)
KR (2)	KR100847172B1 (fr)
CN (4)	CN101343251B (fr)
AR (2)	AR030696A1 (fr)
AT (2)	ATE374772T1 (fr)
AU (2)	AU7493801A (fr)
BE (1)	BE2010C018I2 (fr)
BR (1)	BRPI0111116B8 (fr)
CA (1)	CA2411468C (fr)
CY (4)	CY2010012I2 (fr)
CZ (1)	CZ303176B6 (fr)
DE (4)	DE60139354D1 (fr)
DK (3)	DK1864981T3 (fr)
ES (3)	ES2294000T3 (fr)
FR (1)	FR10C0034I2 (fr)
HK (1)	HK1056114A1 (fr)
HU (3)	HU227476B1 (fr)
IL (5)	IL152988A0 (fr)
LU (1)	LU91681I2 (fr)
MX (1)	MXPA02011621A (fr)
MY (1)	MY136707A (fr)
NO (3)	NO324246B1 (fr)
NZ (2)	NZ533308A (fr)
PL (2)	PL218617B1 (fr)
PT (3)	PT1864981E (fr)
SI (3)	SI1864981T1 (fr)
TW (1)	TWI305207B (fr)
WO (1)	WO2001089457A2 (fr)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001245532B2 (en) *	2000-03-08	2005-08-11	Metabasis Therapeutics, Inc.	Novel aryl fructose-1,6-bisphosphatase inhibitors
CY2010012I2 (el) *	2000-05-25	2020-05-29	Novartis Ag	Μιμητικα θρομβοποιητινης
US20110212054A1 (en) *	2000-05-25	2011-09-01	Glaxosmithkline Llc.	Thrombopoietin mimetics
EP1370252A4 (fr) *	2001-03-01	2006-04-05	Smithkline Beecham Corp	Mimetiques de la thrombopoietine
US7659409B2 (en)	2002-03-19	2010-02-09	Mitsubishi Chemical Corporation	3-Hydroxy-3-(2-thienyl) propionamides and production method thereof, and production method of 3-amino-1-(2-thienyl)-1-propanols using the same
AR040083A1 (es)	2002-05-22	2005-03-16	Smithkline Beecham Corp	Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac
US7414040B2 (en) *	2002-06-06	2008-08-19	Smithkline Beecham Corporation	Thrombopoietin mimetics
WO2004016264A1 (fr)	2002-08-14	2004-02-26	Nissan Chemical Industries, Ltd.	Activateur du recepteur de la thrombopoietine et procede de production
TWI324593B (en)	2002-10-09	2010-05-11	Nissan Chemical Ind Ltd	Pyrazolone compounds and thrombopoietin receptor activator
US20090298179A1 (en) *	2003-04-29	2009-12-03	Connie Erickson-Miller	Methods For Treating Degenerative Diseases/Injuries
US20090048318A1 (en) *	2003-04-29	2009-02-19	Connie Erickson-Miller	Methods for treating degenerative diseases/injuries
US20090143453A1 (en) *	2003-04-29	2009-06-04	Connie Erickson-Miller	Methods for treating degenerative diseases/injuries
WO2004096154A2 (fr)	2003-04-29	2004-11-11	Smithkline Beecham Corporation	Procedes de traitement de maladies/lesions degeneratives
US20100004302A1 (en) *	2003-04-29	2010-01-07	Connie Erickson-Miller	Methods for Treating Degenerative Diseases/Injuries
US7753958B2 (en) *	2003-08-05	2010-07-13	Gordon Charles R	Expandable intervertebral implant
SE0302486D0 (sv) *	2003-09-18	2003-09-18	Astrazeneca Ab	Novel compounds
TW200526638A (en) *	2003-10-22	2005-08-16	Smithkline Beecham Corp	2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005118551A2 (fr) *	2004-05-28	2005-12-15	Ligand Pharmaceuticals Inc.	Composes modulant l'activite de la thrombopoietine et methodes associees
AU2005286593A1 (en) *	2004-09-23	2006-03-30	Reddy Us Therapeutics, Inc.	Novel pyridine compounds, process for their preparation and compositions containing them
CA2583764C (fr) *	2004-10-25	2009-06-09	Ligand Pharmaceuticals, Inc.	Composes et methodes visant a reguler l'activite de la thrombopoietine
CA2588979C (fr)	2004-12-08	2013-01-22	Nissan Chemical Industries, Ltd.	Composes heterocycliques a substitution de 3 ethylidenehydrazino utilises en tant qu'activateurs du recepteur de la thrombopoietine
WO2006064957A1 (fr)	2004-12-14	2006-06-22	Nissan Chemical Industries, Ltd.	Compose d’amide et activateur du recepteur de la thrombopoietine
PE20070083A1 (es)	2005-06-08	2007-01-27	Smithkline Beecham Corp	(5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)amino]-1,3-tiazol-4(5h)-ona
WO2007010954A1 (fr)	2005-07-15	2007-01-25	Nissan Chemical Industries, Ltd.	Composes thiophenes et activateurs du recepteur thrombopoietine
WO2007011056A1 (fr)	2005-07-20	2007-01-25	Nissan Chemical Industries, Ltd.	Composes de pyrazole et activateurs du recepteur de la thrombopoietine
JP2009511603A (ja) *	2005-10-13	2009-03-19	スミスクライン・ビーチャム・コーポレイション	貯蔵中の血小板の有効性を維持する方法
EP1947101A4 (fr)	2005-11-07	2009-09-16	Nissan Chemical Ind Ltd	Composé de type hydrazide et activateur du récepteur de la thrombopoïétine
JP5157900B2 (ja)	2006-06-07	2013-03-06	日産化学工業株式会社	含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤
EP2086551A4 (fr) *	2006-12-01	2011-06-08	Stategics Inc	Mimétique de la thrombopoïetine
UY30915A1 (es) *	2007-02-16	2008-09-02	Smithkline Beecham Corp	Método de tratamiento de canceres
US20110129550A1 (en) *	2007-02-16	2011-06-02	Connie Erickson-Miller	Cancer treatment method
US20110160130A1 (en) *	2007-02-16	2011-06-30	Connie Erickson-Miller	Cancer treatment method
JP2010525072A (ja) *	2007-04-24	2010-07-22	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	Ｔｐｏ模倣薬としてのヒドロキシ−１−アゾ−誘導体の新規な製造方法
ECSP077628A (es)	2007-05-03	2008-12-30	Smithkline Beechman Corp	Nueva composición farmacéutica
CN101888841B (zh) *	2007-10-09	2012-09-26	宾夕法尼亚大学理事会	血小板生成素受体激动剂(TpoRA)杀死急性人骨髓样白血病细胞
CN101481352A (zh) *	2008-01-10	2009-07-15	上海恒瑞医药有限公司	双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
US8236838B2 (en)	2008-04-21	2012-08-07	Institute For Oneworld Health	Compounds, compositions and methods comprising isoxazole derivatives
US8207205B2 (en)	2008-04-21	2012-06-26	Institute For Oneworld Health	Compounds, compositions and methods comprising oxadiazole derivatives
WO2009151862A1 (fr) *	2008-05-15	2009-12-17	Smithkline Beecham Corporation	Procédé de traitement
US20120149749A1 (en) *	2008-10-16	2012-06-14	Michael Arning	Method of treating thrombocytopenia
PE20100362A1 (es)	2008-10-30	2010-05-27	Irm Llc	Derivados de purina que expanden las celulas madre hematopoyeticas
KR20140138349A (ko) *	2009-04-01	2014-12-03	플리바 흐르바츠카 디.오.오.	엘트롬보팩 및 엘트롬보팩 염의 다형체 및 이의 제조 방법
US8343976B2 (en)	2009-04-20	2013-01-01	Institute For Oneworld Health	Compounds, compositions and methods comprising pyrazole derivatives
US8476249B2 (en)	2009-05-07	2013-07-02	Glaxosmithkline Llc	Method of treating thrombocytopenia
WO2010129738A1 (fr) *	2009-05-07	2010-11-11	Glaxosmithkline Llc	Procédé de traitement de la thrombocytopénie
US8680150B2 (en) *	2009-05-28	2014-03-25	Ligand Pharmaceuticals, Inc.	Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors
CA2763768A1 (fr) *	2009-05-29	2010-12-02	Glaxosmithkline Llc	Procedes d'administration de composes agonistes de la thrombopoietine
CN101921232A (zh) *	2009-06-11	2010-12-22	上海恒瑞医药有限公司	双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用
CA2782010A1 (fr)	2009-12-01	2011-06-09	Basf Se	Systeme de resine de pultrusion a base de polyurethane
CN101805291A (zh) *	2010-04-26	2010-08-18	西北大学	1-(4-异丙苯基)-3-甲基-5-吡唑啉酮及其制备方法和应用
JP2013538810A (ja)	2010-09-01	2013-10-17	ノバルティスアーゲー	Ｈｄａｃ阻害剤と血小板減少症薬との組合せ
WO2012102937A2 (fr)	2011-01-25	2012-08-02	Irm Llc	Composés qui développent des cellules souches hématopoïétiques
WO2012121957A1 (fr) *	2011-03-08	2012-09-13	Glaxosmithkline Llc	Association
WO2012121958A2 (fr) *	2011-03-08	2012-09-13	Glaxosmithkline Llc	Association
US20120309796A1 (en)	2011-06-06	2012-12-06	Fariborz Firooznia	Benzocycloheptene acetic acids
WO2013006806A1 (fr) *	2011-07-06	2013-01-10	Cellerant Therapeutics, Inc.	Cellules progénitrices mégacaryocytaires pour la production de plaquettes
US9981918B2 (en) *	2011-08-30	2018-05-29	Chdi Foundation, Inc.	Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2013072921A2 (fr)	2011-09-13	2013-05-23	Glenmark Generics Limited	Procédé de préparation de composés substitués de l'acide 3'-hydrazino-biphényl-3-carboxylique
WO2013049605A1 (fr)	2011-09-28	2013-04-04	Assia Chemical Industries Ltd.	Procédés de préparation d'un intermédiaire dans la synthèse de l'eltrombopag
US9303024B2 (en)	2011-10-11	2016-04-05	Dana-Farber Cancer Institute, Inc.	Pyrazol-3-ones that activate pro-apoptotic BAX
JP6072058B2 (ja)	2011-11-14	2017-02-01	リガンド・ファーマシューティカルズ・インコーポレイテッド	顆粒球コロニー刺激因子受容体と結合する方法および組成物
US9834755B2 (en)	2011-12-08	2017-12-05	Fred Hutchinson Cancer Research Center	Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
PL2807165T3 (pl)	2012-01-27	2019-09-30	Université de Montréal	Pochodne pirymido[4,5-b]indolu i ich zastosowanie do namnażania hematopoetycznych komórek macierzystych
CN103360317B (zh) *	2012-04-11	2016-12-14	齐鲁制药有限公司	双环取代吡唑酮偶氮类衍生物、其制备方法及用途
JP2015154715A (ja) *	2012-05-22	2015-08-27	国立大学法人旭川医科大学	ヒト単核球由来の新規血管再生細胞群及びその分化誘導法
US20140047572A1 (en) *	2012-08-13	2014-02-13	University Of Rochester	Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
US9962370B2 (en)	2013-03-15	2018-05-08	Ligand Pharmaceuticals Incorporated	Methods of treatment associated with the granulocyte colony-stimulating factor receptor
EP2799425A1 (fr)	2013-04-29	2014-11-05	Esteve Química, S.A.	Procédé de préparation d'un agoniste du récepteur de la thrombopoïétine
US9770437B2 (en)	2013-09-02	2017-09-26	Hetero Research Foundation	Compositions of eltrombopag
ITMI20131782A1 (it) *	2013-10-25	2015-04-26	Dipharma Francis Srl	Procedimento per la preparazione di un agonista della trombopoietina
CN104628647A (zh) *	2013-11-12	2015-05-20	上海医药工业研究院	3-甲基-1-(3,4-二甲基苯基)-2-吡唑啉-5-酮的制备方法
CN104725318A (zh) *	2013-12-20	2015-06-24	北京蓝贝望生物医药科技股份有限公司	一种爱曲伯帕的合成方法
WO2015111085A2 (fr)	2014-01-27	2015-07-30	Cadila Healthcare Limited	Procédés de préparation d'eltrombopag et sels pharmaceutiquement acceptables, solvates et intermédiaires de celui-ci
CN103819406B (zh) *	2014-03-17	2015-04-08	苏州明锐医药科技有限公司	艾曲波帕的制备方法
US10647718B2 (en)	2014-04-22	2020-05-12	Universitéde Montréal	Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells
CN105085287A (zh) *	2014-05-12	2015-11-25	上海医药工业研究院	3`-氨基-2`-羟基-[1,1`-联苯]-3-羧酸的制备方法
CN105085276A (zh) *	2014-05-12	2015-11-25	上海医药工业研究院	艾曲波帕中间体及其制备方法和应用
KR20170026633A (ko)	2014-07-17	2017-03-08	씨에이치디아이 파운데이션, 인코포레이티드	Hiv-관련 장애의 치료 방법 및 치료용 조성물
EP3188737A4 (fr)	2014-09-05	2018-05-02	Hetero Research Foundation	Forme cristalline d'acide libre eltrombopag
WO2016055935A1 (fr)	2014-10-06	2016-04-14	Glaxosmithkline Intellectual Property (No.2) Limited	Combinaison d'inhibiteur de déméthylase 1 spécifique à la lysine et d'agoniste de thrombopoïétine
TW201615228A (zh)	2014-10-31	2016-05-01	Nissan Chemical Ind Ltd	配體結合纖維及使用該纖維之細胞培養基材
CN104829593B (zh) *	2015-03-26	2017-08-25	苏州福来兹检测科技有限公司	一种用于检测溶液中金属离子含量的有机化合物及其应用
WO2017042839A1 (fr)	2015-09-08	2017-03-16	Actavis Group Ptc Ehf.	Nouveau sel d'eltrombopag et préparation de celui-ci
MX2018012870A (es)	2016-04-21	2019-03-28	Basf Se	Metodo para la produccion de productos pultruidos a base de poliuretano.
CA3029450C (fr)	2016-06-27	2021-07-13	The General Hospital Corp Dba Massachusetts General Hospital	Stimulation de generation de plaquettes par activation de la biogenese mitochondriale
EP3592793A1 (fr)	2017-03-09	2020-01-15	Basf Se	Formulations de polyuréthane pour la production d'éléments composites
CN107021928B (zh) *	2017-04-01	2022-11-18	常州制药厂有限公司	艾曲波帕新的中间体及其制备方法和应用
EP3395331B1 (fr)	2017-04-26	2019-08-21	Alfred E. Tiefenbacher (GmbH & Co. KG)	Composition de comprimé pharmaceutique comprenant eltrombopag olamine
EP3692021A1 (fr)	2017-10-06	2020-08-12	Assia Chemical Industries Ltd	Formes à l'état solide d'eltrombopag choline
EP3409272B1 (fr) *	2018-03-07	2020-06-24	Alfred E. Tiefenbacher (GmbH & Co. KG)	Composition pharmaceutique comprenant de l'eltrombopag olamine, du sucre réducteur et un liant polymérique
CN110467531B (zh) *	2018-05-09	2022-04-19	新发药业有限公司	一种3’-硝基-2’-羟基联苯-3-甲酸的制备方法
WO2019229572A1 (fr) *	2018-06-01	2019-12-05	Aurobindo Pharma Ltd	Procédé amélioré pour la préparation d'eltrombopag olamine et de ses intermédiaires
EP3604284B1 (fr)	2018-08-02	2020-11-11	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Forme cristalline d du sel de monoéthanolamine d'eltrombopag
EP3604285B1 (fr)	2018-08-02	2020-06-17	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Forme cristalline d1 hautement stable du sel de monoéthanolamine d'eltrombopag
CN113226463A (zh) *	2019-01-08	2021-08-06	江苏恒瑞医药股份有限公司	双环取代吡唑酮偶氮类衍生物的给药方案
CA3143873C (fr)	2019-07-04	2023-09-19	F.I.S. - Fabbrica Italiana Sintetici S.P.A.	Procede de preparation d'intermediaires cles pour la synthese d'eltrombopag ou d'un sel de celui-ci
JP7083793B2 (ja) *	2019-09-10	2022-06-13	Ｊｆｅケミカル株式会社	パラターフェニルテトラカルボン酸およびパラターフェニルテトラカルボン酸二無水物の製造方法
US20210169854A1 (en)	2019-09-20	2021-06-10	Novartis Ag	3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation
WO2021078077A1 (fr) *	2019-10-21	2021-04-29	广东东阳光药业有限公司	Nouvelle forme cristalline d'eltrombopag acétylé et son procédé de préparation
WO2021078076A1 (fr) *	2019-10-21	2021-04-29	广东东阳光药业有限公司	Nouvelle forme cristalline d'eltrombopag acétylé et son procédé de préparation
EP4069203A1 (fr)	2019-12-06	2022-10-12	Synthon B.V.	Composition pharmaceutique comprenant de l'eltrombopag bis(monoéthanolamine)
BR112022010875A2 (pt)	2019-12-06	2022-08-23	Synthon Bv	Comprimido deglutível revestido por película, processo para preparar o comprimido, e, uso de um comprimido
TR202014694A1 (tr)	2020-09-16	2022-03-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Eltrombopag olami̇n i̇çeren bi̇r kati oral farmasöri̇k formülasyon
WO2022201087A1 (fr)	2021-03-25	2022-09-29	Novartis Ag	Formulation d'acide 3'-[(2z)-[1-(3,4-diméthylphényl)-1,5-dihydro-3-méthyl-5-oxo-4h-pyrazol-4-ylidène]hydrazino]-2'-hydroxy-[1,1'-biphényl]-3-carboxylique et de ses sels
CN113336704B (zh) *	2021-06-11	2022-10-11	上海大学	丹参素衍生物及其制备方法和医药用途
CN114507186A (zh) *	2021-12-02	2022-05-17	天津力生制药股份有限公司	一种艾曲波帕的制备方法
EP4436554A1 (fr)	2021-12-15	2024-10-02	Galenicum Health SLU	Compositions pharmaceutiques comprenant de l'eltrombopag
CN116354885A (zh) *	2021-12-27	2023-06-30	苏州特瑞药业股份有限公司	一种艾曲波帕新晶型及其制备方法
WO2025140275A1 (fr) *	2023-12-25	2025-07-03	江苏恒瑞医药股份有限公司	Composé phosphate de dérivé azoïque de pyrazoline substitué ou sel pharmaceutiquement acceptable de celui-ci

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE193350C (fr)
US851444A (en)	1905-11-13	1907-04-23	Agfa Ag	Amido-oxy-sulfonic acid of phenylnaphthimidazol and process of making same.
GB779880A (en)	1953-02-27	1957-07-24	Ciba Ltd	Functional derivatives of azo-dyestuffs containing sulphonic acid groups and processfor making them
US2809963A (en) *	1954-10-26	1957-10-15	Ciba Ltd	Azo-dyestuffs
DE1046220B (de) *	1956-04-21	1958-12-11	Bayer Ag	Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen
GB826207A (en)	1956-07-23	1959-12-31	Bayer Ag	ú´-ú´-dihydroxy-monoazo dyestuffs containing pyrrolidonyl residues and their metal complex compounds
US2950273A (en)	1956-11-20	1960-08-23	Agfa Ag	Process for the production of symmetrical and unsymmetrical azo compounds
US3366619A (en)	1965-04-09	1968-01-30	Interchem Corp	Disazo pyrazolone pigments
US4435417A (en)	1981-02-20	1984-03-06	Gruppo Lepetit S.P.A.	Antiinflammatory 3H-naphtho[1,2-d]imidazoles
ES8503669A1 (es)	1982-07-05	1985-03-01	Erba Farmitalia	Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos.
FR2559483B1 (fr) *	1984-02-10	1986-12-05	Sandoz Sa	Composes heterocycliques contenant des groupes basiques et/ou cationiques, leur preparation et leur utilisation comme colorants
FI91869C (fi)	1987-03-18	1994-08-25	Tanabe Seiyaku Co	Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US4880788A (en)	1987-10-30	1989-11-14	Baylor College Of Medicine	Method for preventing and treating thrombosis
WO1993017681A1 (fr)	1992-03-02	1993-09-16	Abbott Laboratories	Antagonistes du recepteur d'angiotensine ii
IL109570A0 (en)	1993-05-17	1994-08-26	Fujisawa Pharmaceutical Co	Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
EP0638617A1 (fr)	1993-08-13	1995-02-15	Ciba-Geigy Ag	Sels de pigments
DE69412987T2 (de)	1993-12-28	1999-05-27	Dai Nippon Printing Co., Ltd., Tokio/Tokyo	Thermische Übertragungsschicht
SG47030A1 (en) *	1994-01-03	1998-03-20	Genentech Inc	Thrombopoietin
AU691828B2 (en)	1994-02-14	1998-05-28	University Of Washington	Hematopoietic protein and materials and methods for making it
US5482546A (en)	1994-03-30	1996-01-09	Canon Kabushiki Kaisha	Dye, ink containing the same, and ink-jet recording method and instrument using the ink
US5760038A (en)	1995-02-06	1998-06-02	Bristol-Myers Squibb Company	Substituted biphenyl sulfonamide endothelin antagonists
US5746821A (en)	1995-02-13	1998-05-05	Engelhard Corporation	Pigment compositions
ES2303338T3 (es)	1995-06-07	2008-08-01	Glaxo Group Limited	Peptidos y compuestos que se unen a un receptor de trombopoyetina.
US5622818A (en) *	1995-11-29	1997-04-22	Eastman Kodak Company	Color photographic elements containing yellow colored magenta dye forming masking couplers
US5669967A (en)	1996-05-30	1997-09-23	Engelhard Corporation	Pigment compositions
US5932546A (en)	1996-10-04	1999-08-03	Glaxo Wellcome Inc.	Peptides and compounds that bind to the thrombopoietin receptor
SE9701398D0 (sv)	1997-04-15	1997-04-15	Astra Pharma Prod	Novel compounds
GB9715830D0 (en)	1997-07-25	1997-10-01	Basf Ag	Reactive dyes containing piperazine
WO1999011262A1 (fr)	1997-09-02	1999-03-11	Roche Diagnostics Gmbh	Ligands du recepteur mpl, leur procede de preparation, medicaments les contenant et leur utilisation pour le traitement et la prevention de la thrombocytopenie et l'anemie
GB9718913D0 (en)	1997-09-05	1997-11-12	Glaxo Group Ltd	Substituted oxindole derivatives
ES2284217T3 (es)	1997-10-31	2007-11-01	Smithkline Beecham Corporation	Complejos metalicos novedosos.
DE19851389A1 (de)	1998-11-07	2000-05-11	Dystar Textilfarben Gmbh & Co	Gelbe Farbstoffmischungen von wasserlöslichen faserreaktiven Azofarbstoffen und ihre Verwendung
GC0000177A (en) *	1998-12-17	2006-03-29	Smithkline Beecham	Thrombopoietin mimetics
US6750342B1 (en) *	1999-05-19	2004-06-15	Pharmacia Corporation	Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US7026334B1 (en) *	1999-07-26	2006-04-11	Shionogi & Co., Ltd.	Thiazolidine compounds and pharmaceutical compositions exhibiting thrombopoietin receptor agonism
ES2256038T3 (es)	1999-09-10	2006-07-16	Smithkline Beecham Corporation	Mimeticos de trombopoyetina.
DE60032783T2 (de) *	1999-09-24	2007-12-06	Smithkline Beecham Corp.	Thrombopoietinmimetika
WO2001034585A1 (fr)	1999-11-05	2001-05-17	Smithkline Beecham Corporation	Derives de semicarbazone et leur utilisation en tant que mimetiques de la thrombopoietine
EP1104674A1 (fr)	1999-11-10	2001-06-06	Curacyte AG	Colorants o-o'-dihydroxy azoiques dans des médicaments ayant une activité TPO-agoniste ou synergétique
TWI284639B (en)	2000-01-24	2007-08-01	Shionogi & Co	A compound having thrombopoietin receptor agonistic effect
MY133845A (en) *	2000-03-10	2007-11-30	Smithkline Beecham Corp	Il-8 receptor antagonists
US6214813B1 (en)	2000-04-07	2001-04-10	Kinetek Pharmaceuticals, Inc.	Pyrazole compounds
US6436915B1 (en)	2000-04-07	2002-08-20	Kinetek Pharmaceuticals, Inc.	Pyrazole compounds
CY2010012I2 (el) *	2000-05-25	2020-05-29	Novartis Ag	Μιμητικα θρομβοποιητινης
US6642265B1 (en) *	2000-09-08	2003-11-04	Smithkline Beecham Corporation	Thrombopoietin mimetics
EP1349613A4 (fr)	2000-12-19	2005-09-21	Smithkline Beecham Corp	Mimetiques de thrombopoietine
JP2004532614A (ja)	2000-12-21	2004-10-28	スミスクライン・ビーチャム・コーポレイション	金属キレート化アゴニストによる細胞膜受容体の活性化の調節
CA2435143A1 (fr)	2001-01-26	2002-08-01	Shionogi & Co., Ltd.	Composes halogene ayant un agonisme envers le recepteur de thrombopoietine
US7169931B2 (en)	2001-01-26	2007-01-30	Shionogi & Co., Ltd.	Cyclic compounds exhibiting thrombopoietin receptor agonism
EP1370252A4 (fr)	2001-03-01	2006-04-05	Smithkline Beecham Corp	Mimetiques de la thrombopoietine
JP3927001B2 (ja)	2001-06-15	2007-06-06	三菱化学株式会社	色素セット、インクセット並びに記録方法
US6560161B1 (en) *	2001-08-30	2003-05-06	Micron Technology, Inc.	Synchronous flash memory command sequence
EP1450791A1 (fr)	2001-11-30	2004-09-01	Kinetek Pharmaceuticals, Inc.	Derives d'hydrazonopyrazole et leur utilisation comme agents therapeutiques
US20040176372A1 (en)	2002-03-01	2004-09-09	Pintex Pharmaceuticals, Inc.	Pin1-modulating compounds and methods of use thereof
AR040083A1 (es)	2002-05-22	2005-03-16	Smithkline Beecham Corp	Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac
US7414040B2 (en) *	2002-06-06	2008-08-19	Smithkline Beecham Corporation	Thrombopoietin mimetics
TWI324593B (en) *	2002-10-09	2010-05-11	Nissan Chemical Ind Ltd	Pyrazolone compounds and thrombopoietin receptor activator
EP1581527A4 (fr)	2002-12-13	2006-11-22	Smithkline Beecham Corp	Mimetiques de la thrombopoietine
US20090298179A1 (en) *	2003-04-29	2009-12-03	Connie Erickson-Miller	Methods For Treating Degenerative Diseases/Injuries
WO2004096154A2 (fr)	2003-04-29	2004-11-11	Smithkline Beecham Corporation	Procedes de traitement de maladies/lesions degeneratives
TW200526638A (en)	2003-10-22	2005-08-16	Smithkline Beecham Corp	2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005118551A2 (fr) *	2004-05-28	2005-12-15	Ligand Pharmaceuticals Inc.	Composes modulant l'activite de la thrombopoietine et methodes associees
CA2583764C (fr) *	2004-10-25	2009-06-09	Ligand Pharmaceuticals, Inc.	Composes et methodes visant a reguler l'activite de la thrombopoietine
JP2009511603A (ja) *	2005-10-13	2009-03-19	スミスクライン・ビーチャム・コーポレイション	貯蔵中の血小板の有効性を維持する方法
EP2086551A4 (fr) *	2006-12-01	2011-06-08	Stategics Inc	Mimétique de la thrombopoïetine

2000
- 2000-06-03 CY CY2010012C patent/CY2010012I2/el unknown
2001
- 2001-05-23 TW TW090112317A patent/TWI305207B/zh not_active IP Right Cessation
- 2001-05-23 MY MYPI20012430A patent/MY136707A/en unknown
- 2001-05-23 AR ARP010102468A patent/AR030696A1/es active IP Right Grant
- 2001-05-24 AT AT01941599T patent/ATE374772T1/de active
- 2001-05-24 SI SI200130938T patent/SI1864981T1/sl unknown
- 2001-05-24 CZ CZ20023852A patent/CZ303176B6/cs not_active IP Right Cessation
- 2001-05-24 EP EP01941599A patent/EP1294378B1/fr not_active Expired - Lifetime
- 2001-05-24 AU AU7493801A patent/AU7493801A/xx active Pending
- 2001-05-24 HU HU0302257A patent/HU227476B1/hu active Protection Beyond IP Right Term
- 2001-05-24 ES ES01941599T patent/ES2294000T3/es not_active Expired - Lifetime
- 2001-05-24 PT PT07112105T patent/PT1864981E/pt unknown
- 2001-05-24 CN CN2008101297594A patent/CN101343251B/zh not_active Expired - Fee Related
- 2001-05-24 PT PT01941599T patent/PT1294378E/pt unknown
- 2001-05-24 EP EP07112106A patent/EP1889838B1/fr not_active Expired - Lifetime
- 2001-05-24 SI SI200130955T patent/SI1889838T1/sl unknown
- 2001-05-24 DE DE60139354T patent/DE60139354D1/de not_active Expired - Lifetime
- 2001-05-24 DE DE60130760T patent/DE60130760T2/de not_active Expired - Lifetime
- 2001-05-24 DK DK07112105T patent/DK1864981T3/da active
- 2001-05-24 ES ES07112106T patent/ES2334843T3/es not_active Expired - Lifetime
- 2001-05-24 SI SI200130790T patent/SI1294378T1/sl unknown
- 2001-05-24 PT PT07112106T patent/PT1889838E/pt unknown
- 2001-05-24 DE DE122010000037C patent/DE122010000037I1/de active Pending
- 2001-05-24 IL IL15298801A patent/IL152988A0/xx active IP Right Grant
- 2001-05-24 DK DK01941599T patent/DK1294378T3/da active
- 2001-05-24 NZ NZ533308A patent/NZ533308A/en not_active IP Right Cessation
- 2001-05-24 US US10/296,688 patent/US7160870B2/en not_active Expired - Lifetime
- 2001-05-24 HU HU0800710A patent/HU230487B1/hu not_active IP Right Cessation
- 2001-05-24 HK HK03106754.0A patent/HK1056114A1/zh unknown
- 2001-05-24 CN CNA2008101297607A patent/CN101342169A/zh active Pending
- 2001-05-24 BR BRPI0111116A patent/BRPI0111116B8/pt not_active IP Right Cessation
- 2001-05-24 NZ NZ522474A patent/NZ522474A/en not_active IP Right Cessation
- 2001-05-24 KR KR1020077018036A patent/KR100847172B1/ko not_active Expired - Fee Related
- 2001-05-24 EP EP07112105A patent/EP1864981B8/fr not_active Expired - Lifetime
- 2001-05-24 AU AU2001274938A patent/AU2001274938C1/en not_active Expired
- 2001-05-24 MX MXPA02011621A patent/MXPA02011621A/es active IP Right Grant
- 2001-05-24 CN CNB018133401A patent/CN100423721C/zh not_active Expired - Lifetime
- 2001-05-24 KR KR1020027015869A patent/KR100798568B1/ko not_active Expired - Lifetime
- 2001-05-24 PL PL393259A patent/PL218617B1/pl unknown
- 2001-05-24 DE DE60140224T patent/DE60140224D1/de not_active Expired - Lifetime
- 2001-05-24 JP JP2001585703A patent/JP3813875B2/ja not_active Expired - Lifetime
- 2001-05-24 WO PCT/US2001/016863 patent/WO2001089457A2/fr not_active Ceased
- 2001-05-24 CN CN200810129758XA patent/CN101343250B/zh not_active Expired - Fee Related
- 2001-05-24 ES ES07112105T patent/ES2328179T3/es not_active Expired - Lifetime
- 2001-05-24 CA CA002411468A patent/CA2411468C/fr not_active Expired - Lifetime
- 2001-05-24 AT AT07112106T patent/ATE445606T1/de active
- 2001-05-24 PL PL359270A patent/PL216528B1/pl unknown
- 2001-05-24 DK DK07112106.5T patent/DK1889838T3/da active
- 2001-05-24 HU HU0800310A patent/HU230387B1/hu not_active IP Right Cessation
2002
- 2002-11-20 IL IL152988A patent/IL152988A/en active Protection Beyond IP Right Term
- 2002-11-20 NO NO20025566A patent/NO324246B1/no active Protection Beyond IP Right Term
2005
- 2005-12-07 JP JP2005353686A patent/JP4546919B2/ja not_active Expired - Fee Related
2006
- 2006-11-09 US US11/558,071 patent/US7335649B2/en not_active Expired - Fee Related
2007
- 2007-01-05 US US11/620,260 patent/US7332481B2/en not_active Expired - Lifetime
- 2007-01-08 US US11/650,688 patent/US7439342B2/en not_active Expired - Fee Related
- 2007-01-08 US US11/650,838 patent/US7452874B2/en not_active Expired - Lifetime
- 2007-01-08 US US11/650,651 patent/US7473686B2/en not_active Expired - Lifetime
- 2007-12-13 CY CY20071101583T patent/CY1107087T1/el unknown
2008
- 2008-05-02 AR ARP080101867A patent/AR066036A2/es active IP Right Grant
- 2008-06-18 US US12/141,397 patent/US7790704B2/en not_active Expired - Fee Related
- 2008-06-18 US US12/141,379 patent/US7674887B2/en not_active Expired - Fee Related
- 2008-06-18 US US12/141,422 patent/US7648971B2/en not_active Expired - Fee Related
- 2008-08-21 IL IL193617A patent/IL193617A/en not_active IP Right Cessation
- 2008-08-21 IL IL193618A patent/IL193618A0/en not_active IP Right Cessation
- 2008-08-21 IL IL193619A patent/IL193619A0/en unknown
2009
- 2009-08-13 CY CY20091100873T patent/CY1109435T1/el unknown
2010
- 2010-01-11 CY CY20101100027T patent/CY1109730T1/el unknown
- 2010-04-13 BE BE2010C018C patent/BE2010C018I2/fr unknown
- 2010-04-21 LU LU91681C patent/LU91681I2/fr unknown
- 2010-06-18 FR FR10C0034C patent/FR10C0034I2/fr active Active
- 2010-08-19 NO NO2010017C patent/NO2010017I2/no unknown
2020
- 2020-11-19 NO NO2020040C patent/NO2020040I1/no unknown

Also Published As

Publication number	Publication date
DE60139354D1 (de)	2009-09-03
DE60130760T2 (de)	2008-07-17
HUP0302257A2 (hu)	2003-10-28
IL152988A0 (en)	2003-06-24
KR100847172B1 (ko)	2008-07-17
IL152988A (en)	2009-02-11
CY1109730T1 (el)	2014-09-10
HUP0302257A3 (en)	2007-03-28
AU2001274938B2 (en)	2006-01-19
EP1864981B1 (fr)	2009-07-22
US20090176746A1 (en)	2009-07-09
PL216528B1 (pl)	2014-04-30
HUP0800710A2 (hu)	2003-10-28
US20090155203A1 (en)	2009-06-18
HU0800710D0 (en)	2009-01-28
AR030696A1 (es)	2003-09-03
ES2328179T3 (es)	2009-11-10
DK1889838T3 (da)	2010-02-08
MXPA02011621A (es)	2004-05-17
US20080090996A1 (en)	2008-04-17
NO2010017I2 (no)	2012-06-11
IL193617A (en)	2013-06-27
HK1055561A1 (en)	2004-01-16
ES2334843T3 (es)	2010-03-16
HU230387B1 (hu)	2016-03-29
PT1864981E (pt)	2009-08-31
HU230487B1 (hu)	2016-08-29
CN101343251B (zh)	2011-11-09
CY1109435T1 (el)	2014-08-13
BR0111116B1 (pt)	2013-10-08
KR20030060773A (ko)	2003-07-16
CY2010012I2 (el)	2020-05-29
CA2411468A1 (fr)	2001-11-29
SI1864981T1 (sl)	2009-12-31
CA2411468C (fr)	2008-04-15
BRPI0111116B8 (pt)	2021-05-25
IL193618A0 (en)	2009-02-11
HK1056114A1 (zh)	2004-02-06
CY2010012I1 (el)	2012-01-25
KR100798568B1 (ko)	2008-01-28
AU7493801A (en)	2001-12-03
US20070129338A1 (en)	2007-06-07
US20040019190A1 (en)	2004-01-29
WO2001089457A3 (fr)	2002-03-07
EP1864981B8 (fr)	2009-11-11
SI1294378T1 (sl)	2008-02-29
EP1889838A1 (fr)	2008-02-20
US20070179192A1 (en)	2007-08-02
NO2010017I1 (no)	2010-09-20
JP4546919B2 (ja)	2010-09-22
AR066036A2 (es)	2009-07-22
CN101343250B (zh)	2011-09-21
EP1294378A4 (fr)	2004-01-28
DK1864981T3 (da)	2009-09-07
EP1294378B1 (fr)	2007-10-03
NO20025566D0 (no)	2002-11-20
US7160870B2 (en)	2007-01-09
CN101343250A (zh)	2009-01-14
CN101342169A (zh)	2009-01-14
NZ522474A (en)	2004-10-29
NO324246B1 (no)	2007-09-17
US20080090787A1 (en)	2008-04-17
CN1444477A (zh)	2003-09-24
CN101343251A (zh)	2009-01-14
ATE445606T1 (de)	2009-10-15
DE60130760D1 (de)	2007-11-15
US7335649B2 (en)	2008-02-26
JP3813875B2 (ja)	2006-08-23
JP2003534257A (ja)	2003-11-18
DE60140224D1 (de)	2009-11-26
US20080214640A1 (en)	2008-09-04
NO20025566L (no)	2003-01-22
LU91681I9 (fr)	2019-01-03
US7332481B2 (en)	2008-02-19
TWI305207B (en)	2009-01-11
PT1294378E (pt)	2008-01-09
HU0800310D0 (en)	2008-07-28
WO2001089457A2 (fr)	2001-11-29
ES2294000T3 (es)	2008-04-01
BR0111116A (pt)	2003-04-08
PL393259A1 (pl)	2011-07-04
NO2020040I1 (no)	2020-11-19
DK1294378T3 (da)	2008-01-28
PL218617B1 (pl)	2015-01-30
KR20070087255A (ko)	2007-08-27
IL193617A0 (en)	2009-02-11
IL193619A0 (en)	2009-02-11
FR10C0034I2 (fr)	2011-04-29
CY1107087T1 (el)	2012-01-25
CN100423721C (zh)	2008-10-08
PT1889838E (pt)	2010-01-19
DE122010000037I1 (de)	2011-01-27
US7674887B2 (en)	2010-03-09
BE2010C018I2 (fr)	2020-08-20
CZ303176B6 (cs)	2012-05-16
US7452874B2 (en)	2008-11-18
MY136707A (en)	2008-11-28
US7439342B2 (en)	2008-10-21
AU2001274938C1 (en)	2006-09-28
US7648971B2 (en)	2010-01-19
JP2006137764A (ja)	2006-06-01
HU227476B1 (en)	2011-07-28
CZ20023852A3 (cs)	2003-05-14
HK1117825A1 (en)	2009-01-23
SI1889838T1 (sl)	2010-02-26
US7790704B2 (en)	2010-09-07
NZ533308A (en)	2005-10-28
PL359270A1 (en)	2004-08-23
EP1889838B1 (fr)	2009-10-14
EP1294378A2 (fr)	2003-03-26
HK1113057A1 (en)	2008-09-19
FR10C0034I1 (fr)	2010-06-08
US7473686B2 (en)	2009-01-06
US20090176973A1 (en)	2009-07-09
ATE374772T1 (de)	2007-10-15
EP1864981A1 (fr)	2007-12-12

Publication	Publication Date	Title
LU91681I2 (fr)	2010-06-21	"Eltrombopag,éventuellement sous forme d'un sel oud'un solvate (y compris sous forme d'un hydrate) pharmaceutiquement acceptable (REVOLADE)"
LU92428I2 (fr)	2014-06-10	Bosutinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable
NO2024019I1 (no)	2024-04-29	Lenvatinib eller et farmasøytisk akseptabelt salt derav eller et hydrat derav
LU92407I2 (fr)	2014-05-19	Afatinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable, y compris le sel dimaléate
LU91442I2 (fr)	2008-07-21	"Varénicline, optionnellement sous forme d'un sel pharmaceutiquement acceptable, y compris le sel tartrate"
LU88842I2 (fr)	1997-01-27	Nebivolol optionnellement sous forme d'un sel ou d'un hydrate pharmaceutiquement acceptable en particulier hydroclorure de Nebivolol
LU91372I2 (fr)	2007-12-24	Retapamulin optionnellement sous forme d'un sel pharmaceutiquement acceptable (altargo)
LU92939I2 (fr)	2016-03-07	Isavuconbazole en tant que sulfate d'isavuconazonium ou en tant que sel d'isavuconazonium avec tout autre anion pharmaceutiquement acceptable, optionnellement sous forme d'un sel, hydrate ou solvate pharmacuetiquement acceptable
LU91650I2 (fr)	2010-04-19	Saxagliptine et sels pharmaceutiquement acceptables de celle-ci, y compris l'hydrochlorure de saxagliptine - Onglyza-saxagliptin
LU90426I2 (fr)	1999-10-06	Abacavir facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un d-rive y compris le sulfate d'abacavir
LU91599I2 (fr)	2009-10-19	Lasofoxifene, optionnellement sous forme d'un sel d'addition acide, d'un N-oxyde, d'unester ou d'un sel d'ammonium quaternaire, non toxiques et pharmacologiquement acceptables, y compris le sel tartrate (FABLYN - lasofoxifene)
LU93029I2 (fr)	2016-06-14	Alafenamide tenofovir ou un sel ou solvat de celui-ci, en particulier le fumarate d'alafenamide tenofovir
LU93066I2 (fr)	2016-07-11	Combinaison de a) olodatérol, isomèrers optiques individuels de celui-ci, melanges d'énantionmères indiviou de recémates, leurs sels d'addition d'acide avec des acides pharmaceutiquement acceptables, éventuellement sous forme de solvates et/ou hycrates, et b.) un sel de tiotropium ; en particulier une combinaison de a) olodatérol et sis sels d'addition d'acide avec des acides pharmaceutiquement acceptables et b.) du bromure de tiotropium, éventuellement sous forme de solvate et/ou hydrate , plus particulièrement une combinaison de a) hadrochlorure d'olodatérol et b.) de bromure de tiotropium, éventuellement sous forme de monohydrate
LU91710I2 (fr)	2010-09-21	Pazopanib, facultativement sous forme d'un sel ou d'un solvate pharmaceutiquement acceptable de celui-ci
DE60135607D1 (de)	2008-10-16	Ung eines unterirdischen gebiets unter gleichzeitien
DZ3358A1 (fr)	2001-11-29	Formulations en solution pharmaceutiques pour inhalateurs-doseurs sous pression
LU91181I2 (fr)	2005-09-06	Ziconotide, optionnellement sous forme d'un sel avec un acide pharmaceutiquement acceptable, y compris acetate de ziconotide (prialt).
PL357256A1 (en)	2003-06-02	Ship's hull bowl shape
GB0026578D0 (en)	2000-12-13	Heterocyclic derivatives useful as pharmaceutical agents
AU4562000A (en)	2000-11-21	4-(3',4'-heterocyclyl benzoyl) pyrazoles as herbicidal agents
FR2792200B3 (fr)	2001-06-08	Substitut du tabac sous forme d'un comprime ou d'une pastille a sucer
EE200200554A (et)	2004-04-15	Galantamiini või selle farmatseutiliselt sobiva soola kasutamine
WO2001017959A3 (fr)	2001-05-10	Antagonistes du recepteur de la vitronectine
EP1565162A4 (fr)	2011-05-25	Composition sous forme de microemulsion pour l'administration orale de biphenyldimethyldicarboxylate
HUP0302344A3 (en)	2007-03-28	A process for the preparation of alpha-n-acyl alpha' chloroketones